Committees and groups

The Co-design Working Group (CWG) formed in November 2023 to support the co-design of an Enhanced Consumer Engagement Process for Health Technology Assessment (HTA). The group worked to improve how we include the views of consumers and patients earlier in the medicines listing process.

The HTA Review Reference Committee is responsible for overseeing the Health Technology Assessment (HTA) Policy and Methods Review.

The Life Saving Drugs Program (LSDP) Expert Panel considers all applications to list new medicines on the LSDP. The panel assesses medicines and advises the Chief Medical Officer (CMO) about listing medicines. It also reviews medicines already on the program.

The COVID-19 Vaccines and Treatments for Australia – Science and Industry Technical Advisory Group provided advice to the Australian Government on the purchasing and manufacturing of COVID-19 vaccines and treatments.